The purpose of this study is to determine whether avelumab, an investigational antibody
against programmed death-ligand (PD-L1), has an effect on recurrent nasopharyngeal cancer.
Avelumab is designed to block the interaction between programmed cell death protein 1 (PD-1),
a known immune checkpoint, and PD-L1. By blocking this interaction, the immune system may be
stimulated, allowing it to more effectively recognize and attack the cancer.